🔬 [New Drug Spotlight] Casdatifan: A Second-Generation Oral HIF-2α Inhibitor in Clinical Development for ccRCC

Casdatifan is a second-generation, orally bioavailable HIF-2α inhibitor developed by Arcus Biosciences.

[Commercial Synthesis Spotlight] Kilogram-Scale Synthesis and Impurity Profiling of LY104

LY104 is a novel compound designed as a potential therapeutic for chronic obstructive pulmonary disease (COPD), a severe inflammatory airway condition.

🔬 [Commercial Synthesis Spotlight] Scalable Synthesis of Selective PKMYT1 Inhibitor Lunresertib

Lunresertib (RP-6306) is the first selective and orally bioavailable inhibitor of PKMYT1, a serine/threonine kinase that regulates CDK1 activity through phosphorylation.

🔬 [Commercial Synthesis Spotlight] Optimization of the Manufacturing Process for Arformoterol

Arformoterol is the (R, R)-enantiomer of formoterol, a highly potent long-acting β₂-adrenergic agonist used primarily for treating respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma.

[Commercial Synthesis Spotlight] First-Generation Manufacturing Process of GDC-8264

GDC-8264 is a selective inhibitor of RIPK1 (receptor-interacting protein kinase 1), a key regulator of inflammation and cell death pathways. Developed by Genentech, GDC-8264 is being investigated for the prevention of cardiac surgery-associated acute kidney injury (CS-AKI) and other major adverse kidney events (MAKE). Its pharmacological action targets inflammatory responses in autoimmune and neurodegenerative diseases.

[New Drug Spotlight] Dactolisib: A Novel Dual PI3K/mTOR Inhibitor in Clinical Development

Dactolisib is a “first-in-class” dual PI3K/mTOR inhibitor developed by Novartis. Its dual-target mechanism reduces compensatory signaling activation caused by single-target inhibition, providing a potential therapeutic strategy for patients with solid tumors (e.g., breast cancer, renal cell carcinoma) and hematological malignancies harboring PI3K pathway abnormalities.

[Commercial Synthesis Spotlight] First-Generation Process Synthesis and Optimization of S-892216

S-892216 is a second-generation covalent 3CL protease inhibitor developed by Shionogi & Co., Ltd., intended for the treatment of COVID-19. It targets the SARS-CoV-2 3CL protease, an enzyme essential for viral replication. Compared to earlier compounds like ensitrelvir, S-892216 shows superior efficacy and an optimized drug metabolism and pharmacokinetics (DMPK) profile, allowing for lower dosing and enhanced activity.

[New Drug Spotlight] Onradivir: A First-in-Class PB2 Inhibitor Approved for Influenza A Treatment

Onradivir (trade name: Anruiwei®) was approved by China’s NMPA in May 2025 as a treatment for adult patients with acute uncomplicated Influenza A. Developed by Guangdong Zhongsheng Pharmaceutical, Onradivir is the first oral PB2 inhibitor to reach the global market. Its novel cap-snatching mechanism delivers dual antiviral and anti-inflammatory effects, positioning it as a breakthrough therapy against resistant influenza strains.